2291 results about "Acetylation" patented technology

The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.

Disclosed are reagents and methods for reliably detecting the presence and measuring the amount of proteins, including proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a protein or a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided.

The present invention relates to the enhancement of cognition in an individual by delivery of a histone acetylation regulator, such as a histone deacetylase inhibitor. The individual may have normal or poor memory, and the poor memory may be the result of a pathogenic condition or a non-pathogenic condition, such as with normal aging-related impairment. In a specific embodiment, enhancement of cognition occurs in an individual having a mental retardation syndrome.

The present invention provides an intermediate film for laminated glass which can improve the sound-insulating property. The intermediate film for laminated glass according to the present invention has a layered structure including at least two layers, comprising: a first layer containing a polyvinyl acetal resin and a plasticizer; and a second layer positioned on a first surface of the first layer. In a phase diagram of three values including a degree of acetalization, a degree of acetylation, and a hydroxy group content of the polyvinyl acetal resin contained in the first layer, the values of the degree of acetalization, the degree of acetylation, and the hydroxy group content each fall within a region surrounded by a line including four straight lines connecting a first coordinate (degree of acetalization:degree of acetylation:hydroxy group content=70 mol %:30 mol %:0 mol %), a second coordinate (degree of acetalization:degree of acetylation:hydroxy group content=34 mol %:30 mol %:36 mol %), a third coordinate (degree of acetalization:degree of acetylation:hydroxy group content=94 mol %:0 mol %:6 mol %), and a fourth coordinate (degree of acetalization:degree of acetylation:hydroxy group content=100 mol %:0 mol %:0 mol %) in the stated order.

A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., that includes at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.

The invention provides a method for effecting the trans-differentiation of a somatic cell, i.e., the conversion of a somatic cell of one cell type into a somatic cell of a different cell type. The method is practiced by culturing a somatic cell in the presence of at least one agent selected from the group consisting of (a) cytoskeletal inhibitors and (b) inhibitors of acetylation, and (c) inhibitors of methylation, and also culturing the cell in the presence of agents or conditions that induce differentiation to a different cell type. The method is useful for producing histocompatible cells for cell therapy.

This invention is directed to a continuous method for measuring the activity of an enzyme that catalyzes the addition of an acetyl group to a residue capable of being acetylated or an enzyme that catalyzes the removal of an acetyl group from an acetylated residue. In particular the present invention is directed to a continuous method for measuring the activity of histone acetyltranferases and histone deacetylase enzymes.

The present invention relates to a process for the purification of Sucralose of formula (I) which comprises acetylation of substantially impure Sucralose to its penultimate intermediate 4,1',6'-trichloro-4,1',6'-trideoxy galactosucrose penta-acetate (TOPSA) of formula (VI) followed by purification of TOPSA and then deacetylation of purified TOPSA.

The invention relates to a method for producing stem cells having an increased development potential from somatic stem cells, wherein a tissue sample comprising somatic stem cells or a body fluid sample comprising somatic stem cells is taken from an organism, wherein from this tissue sample or body fluid sample as an option somatic stem cells are isolated and/or cultivated, and wherein the thus obtained somatic stem cells are treated with a substance modulating the methylation of the DNA of the cells or a substance modulating the acetylation of chromatin of the cells.

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′-and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.

A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.

The present invention is directed to a pharmaceutical preserving composition comprising: (a) at least one chitosan or chitosan derivative and (b) at least one buffer solution, as well as methods of preserving contact lens solutions and disinfecting contact lens using such composition. The present invention is further directed to a method of preparing O-acetylated chitosan or chitosan derivatives comprising the steps of dissolving the chitosan or chitosan derivative into an aqueous acidic solution and reacting the chitosan or chitosan derivative with an acetylating agent in the presence of a phase transfer reagent.

The invention discloses diacetyl epoxy glyceryl oleates. The general formula of the diacetyl epoxy glyceryl oleates may be (I) or (II). The diacetyl epoxy glyceryl oleates are more stable and flowable than epoxidized soybean oil, the molecular weight of the diacetyl epoxy glyceryl oleates is low, and the diacetyl epoxy glyceryl oleates have high compatibility with polyvinyl chloride (PVC) and arehigh-performance nontoxic plastic plasticizer. The invention also discloses a method for synthesizing diacetyl epoxy glyceryl oleates by starting from oleic acid, which comprises: performing ester exchange of oleic acid and glycerol in the presence of a catalyst to obtain monooleins; compounding monooleins with acetyl to obtain diacetyl monooleins; and performing an epoxidation reaction in an environment with formic acid and hydrogen peroxide, and thus synthesizing diacetyl epoxy glyceryl oleates.

The invention relates to a 5-site or 6-site substituent naphthalimide compound and antitumor applications thereof, which belongs to the fine chemical field. The compound is characterized in that various aliphatic amidogen, heterocyclic amidogen, aryl and Ar aryl are respectively introduced into the 5-site or 6-site of the naphthalimide by a nucleophilic substitution reaction to obtain small molecule compound similar to a lead compound amonafide structure. The small molecule compound has obvious inhibiting activity in vitro test on Hela and P388D1, and wherein, some compounds have stronger cytotoxicity than the amonafide under the same test conditions. In addition, the structures of the compounds take on diversity; the compounds without acetylation sites can be prevented from having the side effect similar to the amonafide; the other compounds with the acetylation sites can be prevented from having the side effect by personalized administration, therefore, the compound has medical application prospect in curing diseases related to tumors.

A composition for repairing and cicatrization of cutaneous lesions of chronic or acute wounds including a hydrogel of chitosan, the degree of acetylation of which is no greater than about 40%.

The invention relates to a construction of an electrochemical luminescence sensor for detecting acetyltransferase activity. The construction comprises the following steps: firstly, polishing, cleaning and activating a gold electrode, assembling captured DNA on the surface of the electrode through action of gold-sulfur bond, and enclosing non-specific binding sites on the surface of the electrode with MCH; then adsorbing a polypeptide chains through electrostatic action, performing acetylation treatment on the polypeptide chains under the action of HATp300, so as to separate from the surface of the electrode; secondly, performing hybrid chain reaction on the electrode in a hybrid chain solution containing two hairpin DNA, and reducing a silver cluster; and finally, detecting electrochemical luminescence signal of the assembled electrochemical luminescence sensor in the solution. The ECL biosensor has remarkable advantages on the quantitative analysis of HAT p300 and the activity analysis on HAT p300 in complicated cell lysis buffering solution.